scPharma snagged $16M for its self-dosed injectables; Insmed suffers a PhII setback for inhaled antibiotic;

> Startup scPharmaceuticals raked in $16 million for its self-dosed injectables in a Series A financing round. Story

> NJ-based Insmed has another setback on its hands with the failure of its Phase II inhaled antibiotic study of Arikayce. But it's going for breakthrough drug designation from the FDA. Story

> Researchers at the U.K.'s University of Warwick have developed a cancer treatment based on the metal iridium which could help shut down tumor cells. More | Abstract

> Aerogen won recognition in China for innovation and leadership for its work in the last two years rolling out its nebulizer products in the country. Article

> The FDA approved Pinnacle Biologics' Optiguide delivery system to treat non-small cell lung and esophageal cancer. Release

Suggested Articles

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.